The overwhelming increase in the prevalence of overweight and obesity in recent years represents one of the greatest threats to the health of the developed world. Among current treatments, however, gastrointestinal (GI) surgery remains the only approach capable of achieving significant weight loss results with long-term sustainability. As the obesity prevalence approaches epidemic proportions, the necessity to unravel the mechanisms regulating appetite control has garnered significant attention. It is well known that physical activity and food intake regulation are the two most important factors involved in body weight control. To regulate food intake, the brain must alter appetite. With this realization has come increased efforts to understand the intricate interplay between gut hormones and the central nervous system, and the role of these peptides in food intake regulation through appetite modulation. This review discusses the central mechanisms involved in body weight regulation and explores a suite of well characterized and intensely investigated anorexigenic and orexigenic gut hormones. Their appetite-regulating capabilities, post-GI surgery physiology and emerging potential as anti-obesity therapeutics are then reviewed.
INTRODUCTION
The overwhelming increase in the prevalence of overweight and obesity in recent years represents one of the greatest threats to the health of the developed world. 1 Aside from the associated increases in morbidity and mortality, the personal, societal and devastating economic consequences have been well documented. 2 Even modest weight loss achieved through currently used approaches can dramatically reduce these consequences, yet gastrointestinal (GI) surgery remains the only treatment offering sustainable weight loss results. Noteworthy, these results have, in part, been linked to alterations in the physiology of circulating gut hormones and their appetite-regulating capabilities. 3 In tandem with the realization of the devastating global obesity epidemic and its related co-morbidities over the last few decades, is the increasing recognition and understanding of the intricate interplay between gut hormones and the central nervous system (CNS), 4 and the regulation of food intake through appetite modulation. 5 Several of these circulating appetite modulators, including ghrelin, the only known orexigenic gut hormone, 6 and a suite of anorexigenic gut hormones, including cholecystokinin (CCK), pancreatic polypeptide (PP), peptide YY (PYY), glucagon-like peptide (GLP)-1, and oxyntomodulin (OXM), have been shown to influence appetite in humans. 7 As a result, there has been increasing momentum aimed at turning this evidence-based knowledge into practical anti-obesity intervention. With all of the current approaches exhibiting problems, 3 and none, except for GI surgery demonstrating long-term efficacy, 8 post-GI surgery gut hormone physiology and gut hormone administration or co-administration may provide vital insight and prove to be useful targets in the ongoing quest for safe and effective antiobesity therapies or treatments.
CENTRAL MECHANISMS IN BODY WEIGHT REGULATION
In the CNS, the hypothalamus is the key region involved in the regulation of appetite. 1 It had previously been hypothesized that satiety was controlled by the ventromedial hypothalamic nucleus, and that feeding was controlled by the lateral region. 9 This early hypothesis has, however, evolved into a much more comprehensive and complex understanding of the integrated neural network responsible for the regulation of appetite, involving discrete pathways within specific nuclei of the hypothalamus, 1 and various regulatory modulators. 10 The regulation of feeding, energy intake and expenditure, and body weight is a homeostatic process. 11 Information regarding general health is communicated predominantly via long-term humoral signals, whereas meal initiation and termination are believed to be regulated via short-term signals, such as neural signals from the brain and humoral signals from the gut. 12 The receipt and integration of these signals occur mainly in the hypothalamus, and are largely regulated by the hypothalamic arcuate nucleus (ARC), located at the base of the region. 1 Gut hormone receptors are located on neuronal populations within the ARC, 3 which is also partially accessible to circulating appetite modulators due to its incomplete isolation from the blood-brain barrier (BBB). 1 Within the ARC, there exists two distinct populations of neurons responsible for appetite regulation; the proopiomelanocortin (POMC) appetite-inhibiting neurons and the neuropeptide Y (NPY) and agouti-related peptide (AgRP) appetitestimulating co-expressing neurons. 13, 14 Signals from the periphery result in changes in the relative activity of these two neuronal sub-populations and the release of their respective neuropeptides, subsequently influencing feeding behavior and energy expenditure.
LONG-TERM ADIPOSITY SIGNALS Leptin Early propositions surrounding the regulation of body weight implicated body fat content as a key player in a so-called adipostat mechanism, 16 which hypothesized the presence of an unknown circulating factor capable of relaying information to the hypothalamus. Several factors were subsequently proposed, but inconclusively proven, until the revolutionary discovery of leptin in 1994. 17 Expressed and secreted exclusively by white adipose tissue adipocytes, the circulating levels of leptin are proportional to fat mass. 1 Either peripheral or central administration of leptin has been demonstrated to reduce food intake and body weight and increase energy expenditure in rodents, 18 and activation of hypothalamic neurons expressing the leptin receptor has suggested the mediation of its effects via this central region.
1 Furthermore, leptin has been shown to inhibit the orexigenic NPY/AgRP co-expressing neurons, and to stimulate the anorexigenic POMC-expressing neurons, within the hypothalamic ARC. 19 Leptin represents one of the core components of the physiological system that controls body weight in mammals. Humans with leptin deficiency are obese, 20 and decreased leptin production from white adipose tissue has been demonstrated to contribute to a plethora of metabolic abnormalities associated with visceral obesity. 21 A study in obese men demonstrated that circulating leptin levels adjusted for body fat were inversely correlated with body weight, suggestive of a leptin deficient state associated with obesity. 21 Therapies using leptin or leptin agonists may, therefore, prove to be useful future tools against obesity-related metabolic disturbances, and therapy involving leptin replacement has to date been shown to result in significant weight loss. 22 Obesity, however, is also often associated with increased circulating leptin levels. 23 This, combined with the lack of expected corresponding leptin-mediated effects, has given rise to the concept of leptin resistance. 24 In many of these cases, despite high circulating levels and the presence of functional receptors, the expected anorexigenic effects of leptin are significantly diminished. 25 Receptor overstimulation, and thus activation of negative feedback loops that serve to block leptin signaling, has been proposed as a possible contributing factor to the development of leptin resistance. 26 In diet-induced obese mice, the ability to reduce food intake and thus body weight in response to peripheral leptin treatment has been demonstrated. 26 In the same model, resistance has been shown to eventually develop to even centrally-administered leptin treatment, 27 and leptin-responsive neurons become incapable of activating downstream signaling pathways of the leptin receptor. 26 Studies in obese rodents have also revealed an impairment of leptin transport across the BBB as being closely associated with leptin resistance. 25 This latter concept has given rise to an alternative explanation wherein restrictive entry of leptin across the BBB results in leptin insufficiency at its central target sites, and perhaps an attenuation in the leptin signaling cascade. 28 
Insulin
As an adiposity signal, insulin is believed to have a similar lipostatic role to that of leptin, although its central effects on food intake and energy homeostasis are less efficient. 29 Similar to leptin, circulating insulin levels are proportional to the degree of adiposity. 30 Central administration of insulin in rodents has been shown to reduce food intake and body weight, 31 and in the ARC, insulin is thought to function through inhibition of NPY/AgRP co-expressing neurons. 10 In addition to sharing some of the appetite-regulating and lipostatic capabilities to that of leptin, insulin is furthermore known to stimulate the synthesis and secretion of leptin from white adipose tissue through a feedback loop referred to as the adipo-insular axis. 32 There are some common hypothalamic targets of leptin and insulin, and evidence of common signal transduction pathways also suggests crosstalk between the two hormones. 33 As with leptin, increased adiposity can lead to a decrease in insulin sensitivity and a state of insulin resistance. 34 Further to this traditional understanding of the consequence of adiposity on insulin and its lipostatic effects, it is also believed that adiposity might in fact be a consequence of insulin resistance itself. 35 With the recognition and identification of insulin resistance as a potential underlying cause of various metabolic abnormalities, particularly including obesity, 36 has come increased investigation aimed at elucidating potential insulin-sensitizing agents. Approaches aimed at improving insulin sensitivity by way of pharmacological intervention remain a driving force in drug development. 37 One such drug, metformin, suppresses hepatic glucose production 38 and has been shown to improve insulin sensitivity in humans. 39 Beneficial weightstabilizing or weight-loss effects of this widely-used drug of choice in clinical practice have also been documented in both diabetic and non-diabetic adults, 40 ,41 adolescents 42 and children. 43 More recently, however, certain data have challenged the safety of these pharmacological approaches. 44 Alternative approaches, in particular those involving plant-based medicinal compounds, have, therefore, been intensely investigated for their potential insulin-sensitizing capabilities. Berberine chloride has been shown to function as an insulin-sensitizing natural product in diabetic rats, 45 and an alcoholic extract of Artemisia dracunculus has shown promising results in primary human skeletal muscle culture. 37 Insulin receptors have been identified in central areas linked to food intake regulation, 46 and it is well established that, in addition to sufficient supply of insulin to the brain, insulin receptor function is vital for energy homeostasis. As with the recently increasing investigation focused on the discovery of insulin-sensitizing agents, products aimed at improving insulin receptor function have also been targeted. Natural products, such as the traditional Chinese medicine Gynostemma pentaphyllum, have been shown to improve glucose tolerance through enhancement of insulin receptor sensitivity in obese diabetic rats, 47 leading to the initiation of human clinical trials. Future research will undoubtedly further elucidate safe and effective natural products as potential insulin-and/or insulin receptor-sensitizers, but there remains a wealth of work to be done in order to unveil the mechanisms of these products.
GUT HORMONES AND OBESITY
The GI tract is the largest endocrine organ in the body and is believed to have an important appetite-regulating role as a source of various regulatory peptide hormones. 5, 15 Post-prandial satiety is believed to be regulated by a sensory system that communicates between the gut and appetite-regulating centers in the brain, with the hypothalamus being responsible for nutrient and energy sensing and corresponding adjustments in food intake. 1 In the gut, there exists a suite of endocrine cells, which synthesize and release various hormones in response to nutrient and energy intake, 1 and it has been demonstrated that these hormones influence appetite in humans and rodents when administered at physiological levels 7, 48 (Table 1) . Distinguishing between genuine satiating effects and reductions in appetite due to nausea or feelings of ill-health can potentially confound experimental results. Food intake is influenced not only by nutritional status but also by various palatability cues, including taste and smell. 49, 50 Dose administration by way of oral gavage can be used to mitigate potential aversion to taste and/or smell and effectively allow for a more critical analysis of the outcomes of such studies. Collectively, unlike leptin and insulin, which have been proposed to signal long-term energy status, gut hormones are thought to have a critical role in meal initiation and termination. 51, 52 Cholecystokinin CCK, the first gut hormone reported to affect appetite, 53 has been shown to dose-dependently reduce food intake in both rats 53 and humans, 54 and in response to meal initiation, plasma levels have been reported to rise within 15 min. 55 Within the GI tract, CCK is predominantly synthesized and released from the duodenum and jejunum, 56 where its local regulatory effects include stimulation of gallbladder contraction and inhibition of gastric emptying. 57 In addition to its GI tract distribution, CCK is also widely distributed within the hypothalamus, predominantly in the median eminence and ventromedial nucleus, and represents the most abundant neuropeptide in the CNS. 58 Centrally-administered CCK has been shown to reduce food intake in rodents, 59 whereas peripheral administration has been shown to reduce food intake in both rodents and humans, through a reduction in meal size and duration. 60 As a result, CCK has been investigated as a potential therapeutic target for the management of obesity. 5 However, compensatory increases in meal frequency, 61 the development of tolerance following infusion (intraperitoneal), 62 and the short half-life of the peptide 63 may undermine the therapeutic utility of CCK. In addition, circulating levels in response to caloric ingestion post-GI surgery have been reported as unchanged. 64 Two CCK receptor subtypes have been characterized, including CCK A and CCK B , in the GI tract and brain, respectively. 63 Of the two, evidence exists for CCK A as being the more important regulator of food intake, 65 and a reversal of the inhibitory effect on food intake following administration of a CCK A antagonist in rats, 66 and increased hunger and meal size in humans, 67 have been shown. In recent years, the main area of therapeutic interest for CCK A receptor agonists has been in obesity treatment. 68 In CCK A receptor knockout rats, there is an elicited increase in meal size and resultant onset obesity, 69 attributable to over-expression of NPY neurons in the ARC. 70 The orally-active CCK A receptor agonist Gl181771X has been shown to safely and effectively inhibit gastric emptying in humans, 71 yet a 24 week double-blind randomized study in obese subjects showed no net reduction in body weight and no beneficial effects on waist circumference. 72 Thus, as with the therapeutic utility of CCK administration, CCK A receptor monotherapy appears to hold minimal promise as a future antiobesity tool. The majority of research into the potential therapeutic utility of CCK and orally-active CCK receptor ligands has, however, taken place in only the last decade. Additional human trials are required to support and strengthen the existing data revealed through both animal and human studies, and future investigations, perhaps involving co-administration with other gut hormones, may be warranted.
Ghrelin
The 28 --amino acid peptide hormone ghrelin, produced predominantly in the stomach, 73 represents the only known orexigenic gut hormone identified to date. 5 Ghrelin binds to the growth hormone secretagogue receptor which is highly expressed in the hypothalamus and brain stem. 74 Although its signaling mechanisms remain to be completely understood, a particularly important role for the hypothalamic ARC and its NPY/AgRP coexpressing neurons has been suggested. 75 Expression of the growth hormone secretagogue receptor has been demonstrated in NPY neurons, 76 and NPY and AgRP antagonists have been shown to abolish ghrelin-induced feeding. Since its discovery in 1999, 73 ghrelin has been proposed to function as a meal initiator, in part due to its potent appetite-stimulating effects in freefeeding rats. 77 Ghrelin has also been shown to stimulate appetite in both lean and obese humans, 78, 79 and infusion (intravenous) in healthy volunteers, at a concentration similar to that observed after a 24 h fast, has been shown to increase appetite and food intake at a buffet-style meal by almost 30%.
1 Subcutaneous injection has also been shown to significantly induce appetite and increase food intake. 80 In obese subjects, fasting ghrelin levels have been shown to be lower compared with normal weight controls and to rise following diet-induced weight loss. 81 The typically expected post-prandial fall in circulating ghrelin levels is also attenuated, or even absent in the obese, 82 suggestive of a role of ghrelin in the pathophysiology of obesity. 83 In contrast, circulating ghrelin levels have been reported as being markedly reduced post-GI surgery, thus potentially enhancing the weight-reducing effect of the procedure. 81 Since this initial study, however, numerous other studies have reported no changes 84, 85 and increases 86, 87 in circulating fasting and post-prandial ghrelin levels following GI surgery, thus highlighting the incomplete understanding of the effect of the surgery on circulating levels of this orexigenic gut hormone. More convincing evidence for the role of ghrelin in energy homeostasis requires that blockage of its signaling results in a decrease in body weight. 88 Pharmacological blockage of ghrelin has been shown to result in decreases in food intake and body weight in rodents, 77 and ghrelin-or ghrelin receptor-deficient rodents are resistant to diet-induced obesity. 89, 90 In diet-induced obese mice, the selective ghrelin receptor antagonist YIL-870 has been shown to promote significant weight reduction through fat mass loss, attributable to the centrally-mediated anorexigenic effects of blocking the growth hormone secretagogue receptor. 91 More evidence is required in support of these findings in humans. It is now well established that ghrelin has a role in overall energy homeostasis, but the pathways that mediate its effects and its role in the effects of GI surgery require further characterization. Weight gain prevention through pre-prandial receptor blockade may represent the most promising role of ghrelin as a useful future anti-obesity agent.
Pancreatic polypeptide The 36-amino acid anorexigenic peptide PP, is primarily synthesized and released from the endocrine pancreas, 15 and to a lesser extent, from the colon and rectum. 5 Levels are low during the fasting state and rise in proportion to caloric intake. 92 Interest in the pharmacological targeting of the Y family of G proteincoupled receptors as an anti-obesity strategy has grown significantly in recent years. 93 Although PP can function on all Y receptors, it has been shown to have the highest affinity for the Y4 receptor, 94 with food intake reduction being completely abolished in Y4 receptor knockout rodents. 95 Peripherally-administered PP reportedly leads to a reduction in food intake, in both rodents and humans. 7, 96 Peripheral PP administration has also been demonstrated to lead to an increase in energy expenditure and a reduction in body weight in rodents, 97 and a demonstrated reduction in appetite and food intake in both lean and obese humans has shed further light on its potential anti-obesity utility. 7 The reported appetite-and energy balance-modulating effects of PP Y4 agonism have been most notably attributed to indirect actions via the brainstem, particularly through modulation of digestive processes, yet the hypothalamus is also believed to have a critical role in PP-mediated food intake reduction. 97 The hypothalamic ARC, which is accessible to PP, 98 expresses Y4 receptors, and administration of PP over a 24 h period in mice has been shown to lead to a significant reduction in NPY mRNA expression. 97 Despite its demonstrated anorexigenic effects and its possible anti-obesity utility, the exact hypothalamic nuclei and downstream pathways through which PP Y4 agonism functions to regulate food intake and body weight have, however, yet to be fully elucidated. 99 A recent study in mice has demonstrated the peripheral PP-mediated suppression of orexigenic pathways in the lateral hypothalamic area, or 'feeding centre', and upregulation of anorexigenic pathways in the ventromedial hypothalamus, or 'satiety centre'. 99 These effects were shown to be mediated via the Y4 receptor, as they were not reproducible in Y4 receptor knockout mice. Although the hypothalamically-regulated anorexigenic effects of PP remain to be fully characterized, a product with the capacity to increase endogenous PP production while avoiding degradation in the circulation, or to increase Y4-mediated signaling, would certainly hold promise as a future anti-obesity tool.
Peptide YY PYY, a member of the PP-fold family of proteins to which PP also belongs, is so named because of the tyrosine residues at both its N-and C-termini. 100 The full-length 36-amino acid peptide is synthesized and released from the L-cells of the GI tract, however, most PYY in the circulation is in the 34-amino acid PYY 3À36 form, having been truncated at the N-terminus. 101 Circulating levels of PYY 3À36 are influenced by meal composition and calorie content, and become elevated within 1 h post-feeding. 102 Similar to PP, peripherally-administered PYY 3À36 exerts its food intake-inhibiting effects via the Y family of G protein-coupled receptors, but with preferentiality for the Y2 receptor. 103 Inhibition of food intake in response to administration of a selective Y2 agonist, 104 and attenuation of this inhibitory effect in response to Y2 antagonists, 105 have provided evidence for this finding. As circulating PYY 3À36 levels are often lower in the obese state, it has been suggested that this characteristic may in fact have a causative role in the development of obesity. 106 From a therapeutic utility standpoint, PYY 3À36 has been shown to have anorexigenic effects in not only normal weight individuals, but also in the obese. In a trial consisting of both lean and obese humans, PYY 3À36 administration (intravenous) lead to a decrease in appetite and an almost 30% restriction in caloric intake in both groups. 107 With the anorexigenic capabilities of exogenous PYY 3À36 being fully intact in the obese, resistance is not thought to exist in the obese state, and this has encouraged longer-term weight loss studies involving chronic administration. Significant increases in circulating PYY 3À36 levels have also been reported post-GI surgery, 108 possibly contributing to the initial and long-term sustainment of weight loss attributed to the procedure. Development of a PYY 3À36 nasal spray for thrice daily administration has been shown to result in modest weight reductions in humans, 109 however, side effects including nausea and vomiting were encountered during clinical trials. This, in addition to previously reported nausea and conditioned taste aversion in mice in response to food intakelowering dosages, 110 has placed limitations on the utility of PYY 3À36 or Y2 receptor agonists as anti-obesity agents. Development of more potent analogs, different administration routes or dosing regiments, or novel combinatorial approaches with other gut hormones may help unlock the future potential of PYY 3À36 as an anti-obesity therapy.
Glucagon-like peptide (GLP)-1
In the gut, GLP-1 is released from small intestinal and colonic L-cells in proportion to ingested calories. 111 In both lean and obese humans, peripherally-administered GLP-1 has been shown to exert anorexigenic effects, 112, 113 with other possible influences on food intake being linked to a reduction in gastric emptying and a suppression of gastric acid secretion. 114 Both centrally-and peripherally-administered GLP-1 or GLP-1 receptor agonists have been shown to enhance satiety, reduce food intake, and promote weight loss in rodents and humans. 115 --117 Obese individuals have been reported to elicit delays in the post-prandial release of GLP-1, and thus present with reduced circulating levels of the peptide. 118 Nonetheless, they remain sensitive to peripherally-administered GLP-1 and its anorexigenic effects. 113 As with PYY, GI surgery has been shown to enhance the post-prandial GLP-1 response. 119 Because of inactivation and clearance by the enzyme dipeptidyl peptidase-IV (DPP-IV), the half-life of GLP-1 is an estimated 5 min, 5 thus presenting a major hurdle down the path to its possible therapeutic utility. Currently investigated approaches against the short half-life of GLP-1 include DDP-IV inhibition and the development of more stable GLP-1 analogs. 120 Inhibition of DPP-IV has had useful applications in the treatment of T2DM, 121 but less promising results have been demonstrated in terms of its antiobesity utility. 120 The development of non-peptidic or DPP-IV resistant GLP-1 receptor agonists have, therefore, been garnering more recent attention, and may show more promise as antiobesity therapies. The GLP-1 analog, exendin-4, discovered from the venom of the Gila monster, Heloderma suspectum, 122 is now being investigated as an anti-obesity agent in non-diabetic humans. Minor, yet adverse side effects, including nausea and vomiting have, however, been reported, 120 thereby placing limitations on its use in terms of a maximum tolerable dose. The highly homologous, long half-life GLP-1 analog, liraglutide, has also been demonstrated as a well-tolerated body weightreducing pharmacological agent in humans, yet transient nausea remains to be the most common side effect. 117, 123 Analogs with greater similarity to the human form of GLP-1 are now in trial, and determination of their efficacy as anti-obesity agents is ongoing. 120 Further to the currently investigated approaches, future research aimed at better understanding the mechanisms involved in endogenous GLP-1 production would be beneficial. With the known additive satiating effects of GLP-1 and PYY, 124 exploiting endogenous GLP-1 production may also yield a novel combinatorial anti-obesity approach.
Oxyntomodulin Early work in rats on a peptide with inhibitory action on stomach oxyntic glands lead to the advent of the name OXM for the now well established gut hormone. 125 OXM shares the same precursor molecule as GLP-1, is co-secreted with GLP-1 following feeding, and its release is also proportional to meal calorie content. 126 Centrally-and peripherally-administered OXM reduces food intake and increases energy expenditure in rodents, and reductions in body weight have been reported in response to chronic injections. 127 Peripheral administration in humans increases satiation and reduces food intake, with repeated injections leading to decreases in body weight. 128 There has also been data in support of OXM promoting increased energy expenditure in humans. 129 The anorexigenic mechanism of action of OXM remains unclear and its role in the pathogenesis of obesity has been largely uninvestigated. 120 Furthermore, a specific OXM receptor has yet to be discovered. 5 As injection of GLP-1 receptor antagonists into the ARC has been demonstrated to block the anorexigenic effects of OXM, 127 it has been proposed that OXM might signal via the GLP-1 receptor, although its receptorbinding affinity is significantly lower. 130 Furthermore, it has recently been shown that OXM requires the GLP-1 receptor, as its effect is abolished in GLP-1 receptor knockout mice. 131 It is also possible that an unknown OXM receptor exists, yet it would almost certainly share similarities with the GLP-1 receptor. Despite the probable involvement of the GLP-1 receptor in OXM signaling, the pathways are likely separate. 127 At equal concentrations, both GLP-1 and OXM elicit anorexigenic effects, despite the large disparity in GLP-1 receptor-binding affinity. 129 Similar to GLP-1, the potential therapeutic utility of OXM may, in part, be hindered due to its inactivation by DPP-IV, 5 although its effects on food intake in humans are more potent, 132 and it is reported to cause less nausea than GLP-1. 15 A recent trial investigating the OXM analog TKS1225 has demonstrated the increasing desirability to develop OXM into an anti-obesity agent. Eliciting comparable satiating effects to GLP-1, 133 along with the already well demonstrated anti-obesity potential of GLP-1, OXM may equally present as a strong gut hormone candidate for combating against the obesity epidemic.
SUMMARY
The prevalence of obesity and its associated co-morbidities has increased substantially in the last number of decades, and the disease is now widely considered to be a global epidemic. Currently, among approved anti-obesity therapies, only GI surgery can effectively lead to substantial weight loss results, accompanied by long-term sustainability. 129 However, GI surgery has largely been rendered impractical as a useful anti-obesity strategy, in large part due to its high cost and rate of mortality. There has, however, been increasingly convincing evidence that the resulting weight loss following the surgery is due, at least in part, to an alteration in the circulating levels and physiology of certain gut hormones. 1, 63 Stimulated release of anorexigenic peptides such as CCK, PP, PYY, GLP-1, and OXM, and diminished release of the orexigenic peptide ghrelin, have been documented. 63 In contrast to some of the currently used, relatively non-specific drug therapies, gut hormones function specifically on systems responsible for appetite control. 129 In addition, due to their natural physiological regulation of appetite, gut hormone-based therapies are less likely to cause adverse side effects than some of the currently approved drugs, 15 thus potentially offering a safer, more attractive alternative approach to combat the obesity epidemic. Although the gut-brain axis and a variety of hormone signaling pathways have been emerging as potentially powerful antiobesity tools, the short half-life of many of the endogenous gut hormones must be considered. 128, 129 Receptor agonists and alternative delivery routes have both been postulated to allow for circumvention of this unfortunate characteristic, and to aid in the future development of gut hormone-based anti-obesity therapies. 15 In conclusion, continued research into the potential to pharmacologically exploit endogenously occurring appetite-regulating gut hormones in an effort to regulate energy homeostasis is required, but certainly holds great promise to lead to the development of safe and effective anti-obesity treatments, and to contribute to the effort of combating the rampant global rise in obesity. The evidence presented herein strongly indicates that obesity research and the development of weight loss or weight management products should focus on the release and function of gut hormones, in connection to their association with receptors in the CNS, in particular the hypothalamus.
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